KRAS and lung carcinoma: Despite impressive evidence of disease control in KRAS G12C-mutant NSCLC indicating clear target engagement, roughly one third to one half of patients did not experience objective response, suggesting a substantial population with incomplete KRAS G12C-dependency; moreover, many patients with KRAS G12C–mutant lung cancer develop resistance to single-agent KRAS G12C inhibitor treatment [12,13].